Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vaccine Boosts Immunity Against Cancer Target

21.07.2004


A therapeutic cancer vaccine being co-developed by the Ludwig Institute for Cancer Research (LICR) and the Australian biotechnology company CSL Limited successfully induced a comprehensive immune response in patients and appeared to delay cancer recurrence, according to a paper published today in the scientific journal, Proceedings of the National Academy of Sciences USA.



The study treated 46 patients, most with melanoma, with three monthly doses of the NY-ESO-1/ISCOMATRIXTM vaccine following surgical removal of the tumor. The vaccine combines a cancer-specific protein, the NY-ESO-1 antigen, with an immune stimulant, the ISCOMATRIXTM adjuvant, from CSL Ltd. In the study, some patients received different doses of the NY-ESO-1/ISCOMATRIXTM vaccine, some received the NY-ESO-1 protein without the ISCOMATRIXTM complex, and some received an inactive placebo. Detailed studies of the patients’ immune responses revealed that the NY-ESO-1/ISCOMATRIXTM vaccine, in contrast to vaccination with the placebo, induced the production of antibodies, and CD8 and CD4 T cells that target the NY-ESO-1 antigen. Vaccination with the NY-ESO-1 protein alone induced fewer responses than the NY-ESO-1/ISCOMATRIXTM vaccine.

“These results are very exciting,” says Dr. Jonathan Cebon, Head of the Joint Austin Health/Ludwig Institute Oncology Unit in Melbourne. “They show that it is possible to stimulate an integrated immune response that has the potential to attack cancer from a number of different angles. Being able to get antibodies, together with both types of T cells, gives us enormous confidence that we are heading in the right direction to develop a clinically effective therapy.”


According to Dr. Cebon, the vaccine also appeared to delay the recurrence of cancer, suggesting that some form of protection is being conferred by the vaccine. “Experience tells us that relapse within the next five years is quite likely in this patient group. So we had a unique opportunity to gather preliminary data on the vaccine’s effect by comparing, over a relatively long period of time, the progress of the group that received the vaccine with the progress of the group that did not.” In a review of the melanoma patients two years later, the researchers found that cancer recurred in five out of seven patients who received the placebo and nine out of 16 who received just the NY-ESO-1 protein. However, of the patients who received the full NY-ESO-1/ISCOMATRIXTM vaccine, 14 out of 19 remained cancer-free.

Despite the encouraging clinical results, the team is quick to point out that this type of retrospective analysis is considered less exact than had it been done in a planned, prospective fashion. “In interpreting these data, we need to be mindful that there may be unforeseen variables that we didn’t control for when we set up the trial,” warns Dr. Ian Davis from the LICR Melbourne Branch, the lead author of the clinical study. “And of course this is a small number of patients.”

The Cancer Vaccine Collaborative (CVC), a partnership established between the international LICR and the Cancer Research Institute (CRI) in New York, will now conduct a large, randomized study of NY-ESO-1/ISCOMATRIXTM vaccine in advanced metastatic melanoma to determine if the immunological and clinical responses do correlate, and whether the vaccine can indeed prevent cancer recurrence. The Phase II study will commence at clinical trials centers in Australia, New Zealand, and the United Kingdom in 2005.

The published studies were supported by the Ludwig Institute for Cancer Research (LICR). The clinical component of the study was conducted at the Austin Hospital, and the Peter MacCallum Cancer Center in Melbourne, Australia. The research team was comprised of researchers from the Melbourne Branch of the LICR based at Austin Hospital, the New York Branch of the LICR in the USA, and the Department of Pathology at Weill Medical College of Cornell University, New York NY, USA. Researchers from CSL Limited, Melbourne, Australia, also contributed to this investigation.

| newswise
Further information:
http://www.licr.org
http://www.csl.com.au

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Thanks for the memory: NIST takes a deep look at memristors

22.01.2018 | Materials Sciences

Radioactivity from oil and gas wastewater persists in Pennsylvania stream sediments

22.01.2018 | Earth Sciences

Saarland University bioinformaticians compute gene sequences inherited from each parent

22.01.2018 | Life Sciences

VideoLinks Wissenschaft & Forschung
Overview of more VideoLinks >>>